$PRTA

SCULLY WILLIAM P purchased $1.0M of PRTA

SCULLY WILLIAM P purchased 125,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.17 ($1.02M total) on 2026-06-11.

Original reporting
SEC EDGAR · SCULLY WILLIAM P
Published Jun 12, 2026, 9:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRTA
Bullish
medium confidence
Mentioned
$PRTA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRTABullishLow
01

Why it matters

This adds a fresh datapoint on insider positioning, which may slightly influence sentiment but does not change the company’s disclosed fundamentals by itself.

02

Market read

A newly filed insider buy (~$1.02M) may provide a small sentiment tailwind, but it is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The article provides no follow-on context (e.g., rationale, lockups, other insider trades, or concurrent company catalysts), so traders should avoid extrapolating to near-term fundamentals.

Relevance 7/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-12 (transaction dated 2026-06-11)

Background

The article is an SEC Form 4 insider transaction disclosure for Prothena (PRTA), reporting a 10% owner open-market purchase.

Company-level read

Ticker impact

$PRTABullishMedium confidence
Context

PRTA disclosed a 10% owner open-market purchase: 125,000 shares bought on 2026-06-11 for ~$1.02M via SEC Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional company-specific news.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is an insider ownership change without new operational/regulatory/clinical information.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Insider purchases under 10b5-1 are not indicated here, but insider buying can still reflect diversification, liquidity planning, or pre-existing intent rather than a new fundamental view.

Key entities

  • PROTHENA CORP PUBLIC LTD CO

    Subject of the SEC Form 4 insider transaction disclosure (PRTA).

  • SCULLY WILLIAM P

    10% owner reporting an open-market purchase of PRTA shares.

Related articles

$PRTAMed

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.

$PRTAMed

PROTHENA CORP PUBLIC LTD CO (PRTA): Results of Operations and Financial Condition

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provide